288397-85-3Relevant academic research and scientific papers
Design and Synthesis of 4,5-disubstituted-thiophene-2-amidines as potent urokinase inhibitors
Rudolph,Illig, Carl R.,Subasinghe, Nalin L.,Wilson, Kenneth J.,Hoffman, James B.,Randle, Troy,Green, David,Molloy, Chris J.,Soll, Richard M.,Lewandowski, Frank,Zhang, Marie,Bone, Roger,Spurlino, John C.,Deckman, Ingrid C.,Manthey, Carl,Sharp, Celia,Maguire, Diane,Grasberger, Bruce L.,DesJarlais, Renee L.,Zhou, Zhao
, p. 491 - 495 (2007/10/03)
A study of the S1 binding of lead 5-methylthiothiophene amidine 3, an inhibitor of urokinase-type plasminogen activator, was undertaken by the introduction of a variety of substituents at the thiophene 5-position. The 5-alkyl substituted and unsubstituted thiophenes were prepared using organolithium chemistry. Heteroatom substituents were introduced at the 5-position using a novel displacement reaction of 5-methylsulfonylthiophenes and the corresponding oxygen or sulfur anions. Small alkyl group substitution at the 5-position provided inhibitors equipotent with 3 but possessing improved solubility.
Compounds and compositons for treating C1s-mediated diseases and conditions
-
, (2008/06/13)
Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4, X, Y and Z are defined in the specification.
Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
-
, (2008/06/13)
The present invention is directed to compounds of Formula I: wherein X is O, S or NR7and R1-R7, Y and Z are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, plasmin and urokinase. Certain of the compounds exhibit direct, selective inhibition of urokinase, or are intermediates useful for forming compounds having such activity.
